Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Rev. saúde pública (Online) ; 50: 70, 2016. graf
Article in English | LILACS | ID: biblio-962220

ABSTRACT

ABSTRACT In the US, where registration of lobbyists is mandatory, the pharmaceutical industry and private health-care providers spend huge amounts of money seeking to influence health policies and government decisions. In Brazil, where lobbying lacks transparency, there is virtually no data on drug industry expenditure to persuade legislators and government officials of their viewpoints and to influence decision-making according to commercial interests. Since 1990, however, the Associação da Indústria Farmacêutica de Pesquisa (Interfarma - Pharmaceutical Research Industry Association), Brazilian counterpart of the Pharmaceutical Research and Manufacturers of America (PhRMA), main lobbying organization of the US pharmaceutical industry, has played a major role in the advocacy of interests of major drug companies. The main goals of Interfarma lobbying activities are: shortening the average time taken by the Brazilian regulatory agency (ANVISA) to approve marketing authorization for a new drug; making the criteria for incorporation of new drugs into SUS (Brazilian Unified Health System) more flexible and speeding up technology incorporation; changing the Country's ethical clearance system and the ethical requirements for clinical trials to meet the need of the innovative drug industry, and establishing a National Policy for Rare Diseases that allows a prompt incorporation of orphan drugs into SUS. Although lobbying affects community health and well-being, this topic is not in the public health research agenda. The impacts of pharmaceutical lobbying on health policies and health-care costs are of great importance for SUS and deserve to be investigated.


Subject(s)
Humans , Drug Approval/economics , Drug Approval/legislation & jurisprudence , Drug Industry/legislation & jurisprudence , Drug Industry/organization & administration , Lobbying , Persuasive Communication , Brazil , Public Health , Conflict of Interest/economics , Conflict of Interest/legislation & jurisprudence
4.
Salud pública Méx ; 50(supl.4): s488-s495, 2008. graf, ilus
Article in Spanish | LILACS | ID: lil-500422

ABSTRACT

Hoy en día, la industria farmacéutica se encuentra en una transición profunda. La globalización y el avance tecnológico representan las principales presiones de cambio para un mercado mundial de medicamentos donde a este tipo de industria le resulta cada vez más difícil recuperar de forma eficiente los costos crecientes de la innovación. México debe analizar las implicaciones en el ámbito político de estos factores de cambio y promover, en el mercado de medicamentos, una política que incremente al máximo las ganancias de salud de los recursos invertidos. La política de medicamentos ofrece un raro ejemplo de complementariedad entre una buena política de salud y una política económica eficiente, es decir, una "política farmacéutica saludable".


Today, the pharmaceutical industry is experiencing a profound transition. Globalization and technological advancement represent the principal pressures for change in the market, where it is increasingly more difficult for this type of industry to efficiently recoup the growing cost of innovation. Mexico needs to analyze the policy implications of these change factors and promote, in the pharmaceutical market, policies that maximize health gains on invested resources. Pharmaceutical policy offers a rare example for a complementary approach between a sound health policy and an efficient economic policy; that is, a "healthy pharmaceutical policy."


Subject(s)
Drug Industry , Health Policy , Drug Costs , Drug Approval/economics , Drug Discovery/economics , Drug Industry/economics , Drug Industry/trends , Economics , Marketing , Mexico , Pharmaceutical Preparations/economics , Therapies, Investigational
5.
Salud pública Méx ; 50(supl.4): s496-s503, 2008. graf, ilus
Article in Spanish | LILACS | ID: lil-500423

ABSTRACT

Las formas que asume la competencia en el mercado definen el nivel de precios. El mercado farmacéutico contiene submercados con diferente grado de competencia; por un lado existen productos innovadores con patente y, por el otro, genéricos con marca comercial o sin ella. Por lo general, los medicamentos innovadores con patente tienen precios monopólicos, pero a su vencimiento éstos bajan al enfrentar la competencia de alternativas terapéuticas. La marca permite conservar las rentas económicas del monopolio. En México los precios de los medicamentos en el mercado privado son elevados, de acuerdo con las estimaciones agregadas y para medicamentos específicos, lo cual refleja las limitaciones de la competencia en el mercado y el poder de la marca comercial. En el segmento público se obtienen precios competitivos con la estrategia de los medicamentos esenciales de la Organización Mundial de la Salud, con base en el listado de productos del Cuadro Básico.


The forms of market competition define prices. The pharmaceutical market contains submarkets with different levels of competition; on the one hand are the innovating products with patents, and on the other, generic products with or without trade names. Innovating medicines generally have monopolistic prices, but when the patents expire prices drop because of competition from therapeutic alternatives. The trade name makes it easier to maintain monopolistic prices. In Mexico, medicine prices in the private market are high -according to aggregated estimates and prices for specific medicines- which reflect the limitations of pharmaceutical market competition and the power of the trade name. The public segment enjoys competitive prices using the WHO strategy for essential medicines on the basis of the Essential List.


Subject(s)
Drug Costs , Drug Industry/economics , Economic Competition , Health Care Sector , Cost Control , Drug Approval/economics , Drug Discovery/economics , Economics , Health Policy , Mexico , Prescription Fees , Pharmaceutical Preparations/classification , Pharmaceutical Preparations/economics , World Health Organization
7.
Ceylon Med J ; 2000 Jun; 45(2): 87-8
Article in English | IMSEAR | ID: sea-48172
SELECTION OF CITATIONS
SEARCH DETAIL